Wave Life Sciences rises after positive data on muscle disorder drug

Wave Life Sciences

26/03/2025 12:51

** Drug developer Wave Life Sciences' WVE.O shares rise 16.1% to $10.96 premarket

** WVE says its experimental drug, WVE-N531, showed functional benefits and reversal of muscle damage in patients with Duchenne muscular dystrophy (DMD) in a mid-stage study

** Most DMD patients lack the protein dystrophin which keeps muscles intact

** Co intends to submit a marketing application to the FDA in 2026 for potential accelerated approval

** Co says 7 out of 8 patients "achieved greater than 5% average dystrophin between 24 and 48 weeks"

** Brokerage Truist Securities says the 48-week data is "impressive" for muscle damage reversal

** Up to last close, WVE has risen 63.3% in the past 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))